Cardiovascular effects of approved drugs for rheumatoid arthritis
F Atzeni, J Rodríguez-Carrio, CD Popa… - Nature Reviews …, 2021 - nature.com
The risk of cardiovascular disease is increased in patients with rheumatoid arthritis
compared with the general population owing to the influence of traditional and non …
compared with the general population owing to the influence of traditional and non …
Anti-inflammatory therapy for atherosclerosis: focusing on cytokines
AV Poznyak, D Bharadwaj, G Prasad… - International journal of …, 2021 - mdpi.com
Atherosclerosis is a well-known global health problem. Despite the high prevalence of the
disease, numerous aspects of pathogenesis remain unclear. Subsequently, there are still no …
disease, numerous aspects of pathogenesis remain unclear. Subsequently, there are still no …
Inflammatory mechanisms in COVID-19 and atherosclerosis: current pharmaceutical perspectives
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The …
coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The …
Inflammation in coronary microvascular dysfunction
Chronic low-grade inflammation is involved in coronary atherosclerosis, presenting multiple
clinical manifestations ranging from asymptomatic to stable angina, acute coronary …
clinical manifestations ranging from asymptomatic to stable angina, acute coronary …
The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation
that, if left untreated, can cause joint destruction and physical impairments. The inflammatory …
that, if left untreated, can cause joint destruction and physical impairments. The inflammatory …
The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients
While the most common manifestations associated with rheumatoid arthritis (RA) are
synovial damage and inflammation, the systemic effects of this autoimmune disorder are life …
synovial damage and inflammation, the systemic effects of this autoimmune disorder are life …
[HTML][HTML] Atherosclerotic cardiovascular disease in rheumatoid arthritis: impact of inflammation and antirheumatic treatment
AM Kerola, S Rollefstad, AG Semb - European Cardiology Review, 2021 - ncbi.nlm.nih.gov
Patients with rheumatoid arthritis (RA) are at approximately 1.5-fold risk of atherosclerotic
cardiovascular disease (CVD) compared with the general population, a phenomenon …
cardiovascular disease (CVD) compared with the general population, a phenomenon …
Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study
E Toussirot, H Marotte, D Mulleman, G Cormier… - Arthritis research & …, 2020 - Springer
Background Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular
(CV) disease. Adiponectin is involved in the metabolism of glucose and lipids with …
(CV) disease. Adiponectin is involved in the metabolism of glucose and lipids with …
Cardiovascular risk assessment in rheumatoid arthritis: accelerated atherosclerosis, new biomarkers, and the effects of biological therapy
Rheumatoid arthritis (RA), one of the most common of the chronic inflammatory autoimmune
diseases (CIADs), is recognized as an independent cardiovascular risk factor. Traditional …
diseases (CIADs), is recognized as an independent cardiovascular risk factor. Traditional …
Treatment of cardiovascular disease in rheumatoid arthritis: a complex challenge with increased atherosclerotic risk
S Ahmed, B Jacob, SE Carsons, J De Leon, AB Reiss - Pharmaceuticals, 2021 - mdpi.com
Rheumatoid arthritis (RA) carries significant risk for atherosclerotic cardiovascular disease
(ASCVD). Traditional ASCVD risk factors fail to account for this accelerated atherosclerosis …
(ASCVD). Traditional ASCVD risk factors fail to account for this accelerated atherosclerosis …